Portal de Periódicos da CAPES

LSD‐25 AND THE STATUS AND LEVEL OF BRAIN SEROTONIN *

1962; Wiley; Volume: 96; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1962.tb50105.x

1749-6632

Daniel X. Freedman, Nicholas J. Giarman,

Cancer, Stress, Anesthesia, and Immune Response

Annals of the New York Academy of SciencesVolume 96, Issue 1 p. 98-107 LSD-25 AND THE STATUS AND LEVEL OF BRAIN SEROTONIN * Daniel X. Freedman, Daniel X. Freedman Psychopharmacology Laboratory, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, Conn.Search for more papers by this authorNicholas J. Giarman, Nicholas J. Giarman Psychopharmacology Laboratory, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, Conn.Search for more papers by this author Daniel X. Freedman, Daniel X. Freedman Psychopharmacology Laboratory, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, Conn.Search for more papers by this authorNicholas J. Giarman, Nicholas J. Giarman Psychopharmacology Laboratory, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, Conn.Search for more papers by this author First published: January 1962 https://doi.org/10.1111/j.1749-6632.1962.tb50105.xCitations: 49 * The work described in this paper was supported in part by Research Grants M-1204 and MY-3363 from the National Institute of Mental Health, Public Health Service, Bethesda, Md. and the Wyeth Laboratories Fund, Philadelphia, Pa. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Woolley, D. W. & E. Shaw. 1954. Proc. Natl. Acad. Sci. 40: 228. 10.1073/pnas.40.4.228 CASPubMedWeb of Science®Google Scholar 2 Gaddum, J. H. & K. A. Hameed. 1954. Brit. J. Pharmacol. Chemotherapy. 9: 240. 10.1111/j.1476-5381.1954.tb00848.x CASPubMedWeb of Science®Google Scholar 3 Shaw, E. & D. W. Woolley. 1956. Science.. 124: 121. 10.1126/science.124.3212.121 CASPubMedGoogle Scholar 4 Costa, E. 1956. Proc. Soc. Exptl. Biol. Med. 91: 39. 10.3181/00379727-91-22163 CASPubMedWeb of Science®Google Scholar 5 Kety, S. S. 1959. Science.. 129: 1590. 10.1126/science.129.3363.1590 CASPubMedWeb of Science®Google Scholar 6 Schain, R. J. & D. X. Freedman. 1961. J. Pediat. 58: 315. 10.1016/S0022-3476(61)80261-8 CASPubMedWeb of Science®Google Scholar 7 Freedman, D. X. & A. J. Benton. 1961. New Engl. J. Med. 264: 529. CASPubMedWeb of Science®Google Scholar 8 Marrazzi, A. S. & E. R. Hart. 1955. EEG Clin. Neurophysiol. 7: 146. Web of Science®Google Scholar 9 Bradley, P. B. & A. J. Hance. 1956. EEG Clin. Neurophysiol. 8: 699. Web of Science®Google Scholar 10 Tedeschi, D. H., R. E. Tedeschi & E. J. Fellows. 1959. J. Pharmacol. Exptl. Therapeutics. 126: 223. CASPubMedWeb of Science®Google Scholar 11 Freedman, D. X. 1960. Federation Proc.. 19: 266. Web of Science®Google Scholar 11a Freedman, D. X. J. Pharmacol. Exptl. Therapeutics. In press. Google Scholar 12 Brodie, B. A., P. A. Shore & A. Pletscher. 1956. Science.. 123: 992. 10.1126/science.123.3205.992-a CASPubMedWeb of Science®Google Scholar 13 Amin, A. H., T. B. Crawford & J. H. Gaddum. 1954. J. Physiol. 126: 596. 10.1113/jphysiol.1954.sp005229 CASPubMedWeb of Science®Google Scholar 14 Paasonen, M. K. & N. J. Giarman. 1958. Arch intern. pharmacodynamic.. 114: 189. CASPubMedWeb of Science®Google Scholar 15 Freedman, D. X., G. K. Aghajanian, B. Rosner & E. M. Ornitz. 1958. Science.. 127: 1173. 10.1126/science.127.3307.1173 CASPubMedWeb of Science®Google Scholar 16 Giarman, N. J. &. S. Schanberg. 1958. Biochem. Pharmacol. 1: 301. 10.1016/0006-2952(59)90118-2 Web of Science®Google Scholar 17 Axelrod, J., R. O. Brady, B. Witkop & E. V. Evarts. 1957. Ann N. Y. Acad. Sci. 66 (3): 435. 10.1111/j.1749-6632.1957.tb40739.x CASPubMedWeb of Science®Google Scholar 18 Bogdanski, D. F., H. Weissbach & S. Udenfriend. 1958. J. Pharmacol. Exptl. Therapeutics. 122: 182. CASPubMedWeb of Science®Google Scholar 19 Schanberg, S. M. Ph. D. Dissertation. Yale Univ. New Haven, Conn. Google Scholar 20 Giarman, N. J. Federation Proc. In press. Google Scholar 21 Pepeu, G. & N. J. Giarman. 1960. Federation Proc.. 19: 1. Google Scholar 22 Freedman, D. X. & G. K. Aghatanian. 1959. Federation Proc.. 18: 390. Web of Science®Google Scholar 23 Balestrieri, A. 1957. In Psychotropic Drugs. S. Garattini & V. Ghetti, Eds. Elsevier. Amsterdam , The Netherlands . Google Scholar 24 Isbell, H., E. J. Miner & C. R. Logan. 1959. Psychopharmacologia.. 1: 20. 10.1007/BF00408108 CASPubMedWeb of Science®Google Scholar Citing Literature Volume96, Issue1Some Biological Aspects of Schizopherenic BehaviorJanuary 1962Pages 98-107 ReferencesRelatedInformation